Mark Samson, MD
Family Medicine · Dublin, GANPI 1386637189
Payments from drug & device makers
Across 189 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$475
- Pfizer$316
- AbbVie$294
- Johnson & Johnson$290
- Amgen$216
- GSK$215
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,02498%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 29 | $475 |
| Pfizer | 19 | $316 |
| AbbVie(2 entities) | 16 | $294 |
| Johnson & Johnson | 21 | $290 |
| Amgen | 18 | $216 |
| GSK | 16 | $215 |
| AstraZeneca | 11 | $183 |
| Novartis | 10 | $161 |
| Merck | 10 | $149 |
| Esperion Therapeutics, Inc. | 1 | $96 |
| Philips North America LLC | 3 | $77 |
| Seqirus USA Inc | 3 | $65 |
| Zealand Pharma US, Inc. | 5 | $63 |
| Abbott | 4 | $62 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $42 |
| Medtronic | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Biogen | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$3,079 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 267 | $232,755 |
| OzempicSemaglutide | 179 | $184,172 |
| EliquisApixaban | 213 | $174,375 |
| RybelsusSemaglutide | 107 | $126,734 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 131 | $114,948 |
| FarxigaDapagliflozin Propanediol | 98 | $70,446 |
| MounjaroTirzepatide | 47 | $51,079 |
| JanuviaSitagliptin Phosphate | 39 | $38,453 |
| XareltoRivaroxaban | 39 | $37,906 |
| MyrbetriqMirabegron | 70 | $36,193 |
| GlyxambiEmpagliflozin/Linagliptin | 38 | $34,821 |
| TrulicityDulaglutide | 30 | $32,711 |
| EntrestoSacubitril/Valsartan | 31 | $27,629 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 43 | $24,168 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $21,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat, Tradjenta, Spiriva Respimat | $27 | $343,033415 claims |
| PfizerEliquis | $316 | $174,375213 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $215 | $128,831188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $183 | $100,218159 claims |
| Lilly USA, LLCMounjaro, Trulicity | $17 | $83,79077 claims |
| MerckJanuvia | $149 | $38,45339 claims |
| Johnson & JohnsonXarelto | $290 | $37,90639 claims |
| Astellas Pharma US IncMyrbetriq | $475 | $36,19370 claims |
| NovartisEntresto | $161 | $27,62931 claims |
| AbbVieLinzess | $294 | $10,04915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $20 | $6,74212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Dublin
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.